Ark Therapeutics Group Plc - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Ark Therapeutics Group Plc Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Ark Therapeutics Group Plc. The Group's principal activity is discovering, developing and commercialising products in areas of specialist medicine with particular focus on vascular disease and cancer. Its pharmaceutical business focuses on gene-based medicine that harnesses healthy brain cells to destroy cancer cells that attempt to proliferate. It is used for the treatment of patients with operable high-grade glioma, where the average survival period for patients, once diagnosed, is about eight months. It also has products designed to prevent the blocking of veins after vascular surgery. Product brands are Cerepro, Vitor and Trinam. In addition, the Group also has wound care portfolio centered on the prevention and treatment of foot, lower-leg and infected wounds. Its product brands include Kerrabot, Kerraped, Neuropad and Flaminal. The Group operates in the United Kingdom and Finland.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report